[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-436573-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-436573-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","clinicopathological-characteristics-and-treatment-outcomes-of-luminal-b1-breast-cancer-in-taiwan","Clinicopathological characteristics and treatment outcomes of luminal B1 breast cancer in Taiwan","","Hormone receptor-positive, HER2-negative luminal B1 breast cancer shows a higher relapse risk than luminal A in prior evidence. This observational study compared distant metastasis patterns and clinical outcomes between luminal B1 and luminal A in an Asian cohort. Patients with ER-positive, HER2-negative tumors undergoing surgery from 2009–2016 were classified by immunohistochemistry. Luminal B1 patients were younger with larger tumors and more adverse nodal and pathological features.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinicopathological-characteristics-and-treatment-outcomes-of-luminal-b1-breast-cancer-in-taiwan/436573/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinicopathological-characteristics-and-treatment-outcomes-of-luminal-b1-breast-cancer-in-taiwan/436573.png","ImageObject",300,407,{"name":42,"@type":43},"Maya Linwood","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-01","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":22},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"How were patients classified into luminal B1 or luminal A subtypes?","Question",{"text":62,"@type":63},"Patients with estrogen receptor-positive, HER2-negative breast cancer were classified via immunohistochemical analysis into luminal A or luminal B1 subsets.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"What differences did the study observe in tumor and nodal features between luminal B1 and luminal A?",{"text":67,"@type":63},"Luminal B1 patients were younger and had larger tumors, with a higher degree of affected axillary lymph nodes and higher rates of lymphovascular invasion and tumor necrosis.",{"name":69,"@type":60,"acceptedAnswer":70},"Did luminal B1 and luminal A differ in distant metastatic sites?",{"text":71,"@type":63},"Higher local recurrence and distant metastasis rates were seen in luminal B1, but no difference was observed in specific distant metastatic sites between the groups.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},436573,1790815672,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":22,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","J Chin MedAssoc  \nOriginal article  \nClinicopathological characteristics and treatment outcomes of luminal B1 breast cancer in Taiwan  \nBo-Fang Chena, Yi-Fang Tsaia,b,c,*, Chi-Cheng Huangb,d,e, Chih-Yi Hsuc,f, Pei-Ju Lienb,g, Yu-Ling Wangd, Yen-Shu Lina,b, Chin-Jung Fengb,c,h, Kuang-Liang Kinga, Jen-Hwey Chiub,c, Gar-Yang Chaua,c,  \nLing-Ming Tsenga,b,c,i,*  \naDivision of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; bComprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; cFaculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; dDivision of Experimental Surgery, Department of Surgery Taipei Veterans General Hospital, Taipei, Taiwan, ROC; eSchool of Public Health, College of Public Health, National Taiwan University Hospital, Taipei, Taiwan, ROC; fPathology and Laboratory Medicine Department, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; gDepartment of Nurse, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; hDivision of Plastic and Reconstructive Surgery, Department of Surgery Taipei Veterans General Hospital, Taipei, Taiwan, ROC; iDepartment of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, ROC  \nAbstract  \nBackground: Hormone receptor-positive, human epidermal growth factor receptor II (HER2)-negative luminal B1 breast cancer is associated with a higher risk of disease relapse than luminal A breast cancer. Therefore, we assessed and compared the distant metastasis pattern and clinical outcomes associated with luminal B1 and luminal A breast cancer in an Asian population. Methods: In this observational study, we assessed patients with estrogen receptor-positive, HER2-negative breast cancer who underwent surgery from 2009 to 2016. Patients were classified into luminal A or luminal B1 subsets via immunohistochemical analysis. Disease-free survival, post-metastasis survival, and overall survival were estimated; time to disease relapse and patterns of distant metastasis were compared. Risk of relapse and mortality were assessed using Cox proportional hazards model. Results: Patients with luminal B1 breast cancer (n = 677) were significantly younger and had larger tumors and a higher degree of affected axillary lymph nodes, lymphovascular invasion, and tumor necrosis than those with luminal A breast cancer (n = 630) . Higher rates of local recurrence and distant metastasis were observed for luminal B1 (both p \u003C 0.05); however, no difference was observed in the specific distant metastatic sites. We observed a significant increase in disease relapse risk in luminal B1 patients compared with that in luminal A (hazard ratio: 2. 157, 95% CI: 1.340-3.473, p \u003C 0.05) . Patient age, tumor size, stage, lymphovascular invasion, and receiving chemotherapy and hormone therapy were independent risk factors for metastasis and recurrence. Only the luminal B1 subtype (hazard ratio: 5.653, 95% CI: 1.166-27.409, p \u003C 0.05) and stage (hazard ratio: 3.400, 95%  \nCI: 1.512-7.649, p \u003C 0 .05) were identified as independent risk factors for post metastatic mortality.  \nConclusion: Luminal B1 breast cancer has aggressive tumor biology compared with luminal A breast cancer in the follow-up period. However, there was no significant difference in the disease relapse pattern between the groups.  \nKeywords: Breast cancer; Distant metastasis; Luminal A; Luminal B1  \n1. INTRODUCTION  \nBreast cancer is a common cancer in women globally, with an increasing incidence rate in Taiwan.1 The conventional prognostic parameters, including tumor size, lymph node involvement, nuclear grade, and lymphovascular invasion, provide important information regarding tumor behavior and anatomical  \n*Address correspondence. Dr. Ling-Ming Tseng and Dr. Yi-Fang Tsai, Division of General Surgery, Taipei Veterans General Hospital, 201, Section 2, Shi-Pai Road,  \nTaipei 112, Taiwan, ROC. E-mail address: [lmtsen","cbCainKyI8BA5ulo","https://ap.wps.com/l/cbCainKyI8BA5ulo","pdf",712065,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"How were patients classified into luminal B1 or luminal A subtypes?\",\"answer\":\"Patients with estrogen receptor-positive, HER2-negative breast cancer were classified via immunohistochemical analysis into luminal A or luminal B1 subsets.\"},{\"question\":\"What differences did the study observe in tumor and nodal features between luminal B1 and luminal A?\",\"answer\":\"Luminal B1 patients were younger and had larger tumors, with a higher degree of affected axillary lymph nodes and higher rates of lymphovascular invasion and tumor necrosis.\"},{\"question\":\"Did luminal B1 and luminal A differ in distant metastatic sites?\",\"answer\":\"Higher local recurrence and distant metastasis rates were seen in luminal B1, but no difference was observed in specific distant metastatic sites between the groups.\"}]","Clinicopathological characteristics and treatment outcomes of luminal B1 breast cancer in Taiwan | PDF",1790678414]